MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Orthofix Medical EBITDA 2011-2025 | OFIX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Orthofix Medical
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.6 M | -86 M | 15.8 M | 21.3 M | 24.3 M | 40.1 M | 51.8 M | 58.5 M | 58.3 M | 39.3 M | 35 M | 29.7 M | 93.1 M | 94.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 94.6 M | -86 M | 32.2 M |
Quarterly EBITDA Orthofix Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.1 M | 868 K | -14.4 M | - | -3.73 M | -10.9 M | -14.5 M | - | -11.4 M | -23.3 M | -47 M | - | 1.78 M | 13.2 M | 4.44 M | - | 6.84 M | 11.8 M | 4.53 M | - | 13.2 M | -14.1 M | 13.2 M | 4.1 M | -12.6 M | 6.63 M | 1.28 M | 12.4 M | 8.64 M | 10.5 M | 12.2 M | 17.9 M | 24.5 M | 18.4 M | 11 M | 7.42 M | 24.8 M | 7.31 M | 11.9 M | 7.38 M | 4.14 M | 4.93 M | -6.79 M | 3.95 M | 7.02 M | 7.36 M | 5.72 M | -10.1 M | 1.48 M | 17.2 M | 11.1 M | 26.5 M | 32.6 M | 27.7 M | 20.5 M | 8.17 M | 38.2 M | 23.7 M | -30.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.2 M | -47 M | 5.43 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.86 | -3.26 % | $ 134 M |  USA |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Abiomed
ABMD
|
254 M | - | - | $ 17.2 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
421 M | $ 307.92 | -1.93 % | $ 8.69 B | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 45.13 | -2.67 % | $ 6.72 K | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
8.16 B | $ 125.1 | 1.48 % | $ 218 B | USA |
 |
Boston Scientific Corporation
BSX
|
3.87 B | $ 92.34 | 0.64 % | $ 136 B | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 2.56 | 8.94 % | $ 95.5 M |  France |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 0.92 | -4.72 % | $ 14.8 M | USA |
 |
IRadimed Corporation
IRMD
|
22.8 M | $ 96.35 | -1.06 % | $ 1.22 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-15.9 M | $ 17.7 | -3.46 % | $ 408 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
154 M | $ 62.79 | -1.82 % | $ 3.41 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
-56.6 M | $ 2.53 | 0.86 % | $ 99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.56 | 0.76 % | $ 1.15 B | Israel |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 9.88 | 0.05 % | $ 709 M | Israel |
 |
Myomo
MYO
|
-10.5 M | $ 1.06 | -1.85 % | $ 7.47 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 13.41 | -4.56 % | $ 1.03 B | USA |
 |
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | USA |
 |
Align Technology
ALGN
|
753 M | $ 165.15 | 0.78 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
14 M | $ 1.07 | -3.18 % | $ 110 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-18.8 M | $ 12.81 | -1.23 % | $ 346 M | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 14.86 | -0.03 % | $ 97.4 M | USA |
 |
AxoGen
AXGN
|
3.18 M | $ 30.33 | 1.15 % | $ 1.34 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
217 M | $ 40.78 | 2.33 % | $ 1.26 B | USA |
|
LENSAR
LNSR
|
-7.7 M | $ 11.48 | -0.17 % | $ 132 M | USA |